GI
PRVL

GAMCO Investors’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

GAMCO Investors’s Portfolio PRVL Stock Details PRVL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-28,500
Closed -$657K – 951
2020
Q4 		$657K Buy
+28,500
New +$361K 0.01% 681

GAMCO Investors's PRVL Position: Q1 2021 in Review

GAMCO Investors sold out of Prevail Therapeutics Inc. Common Stock (PRVL) in Q1 2021, closing a stake of 28,500 shares — an estimated $657K sold.

GAMCO Investors first reported a position in PRVL in Q4 2020 and held it in 1 quarter. The position peaked at $657K in Q4 2020. 0 funds tracked by Wall St. Rank hold PRVL as of Q1 2021.

  • GAMCO Investors reported no remaining Prevail Therapeutics Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • GAMCO Investors sold 28,500 Prevail Therapeutics Inc. Common Stock shares in Q1 2021, an estimated $657K.
  • GAMCO Investors first reported a position in Prevail Therapeutics Inc. Common Stock in Q4 2020 and held it in 1 quarter.
  • GAMCO Investors's Prevail Therapeutics Inc. Common Stock position peaked at $657K in Q4 2020.
  • 0 funds tracked by Wall St. Rank held Prevail Therapeutics Inc. Common Stock as of Q1 2021.

Based on GAMCO Investors's 13F filing for Q1 2021, filed 14 May 2021.